Table 1.
Baseline Characteristics.
| Characteristics | All patients | Anagliptin | Sitagliptin |
|---|---|---|---|
| (n = 353) | (n = 177) | (n = 176) | |
| Age-years, mean (SD) | 68 (10) | 68 (10) | 68 (9) |
| Gender male, n (%) | 214 (61) | 110 (62) | 104 (59) |
| Body mass index-kg/m2, mean (SD) | 26.2 (3.8) | 26.5 (4.0) | 25.9 (3.5) |
| Waist circumference-cm, mean (SD) | 93.2 (10.5) | 93.7 (11.2) | 92.8 (9.6) |
| Systolic blood pressure-mmHg, mean (SD) | 133 (16) | 134 (16) | 132 (16) |
| Diastolic blood pressure-mmHg, mean (SD) | 72 (12) | 74 (12) | 71 (11) |
| Heart rate-bpm, mean (SD) | 73 (11) | 74 (12) | 71 (11) |
| History of acute coronary syndrome, n (%) | 88 (25) | 53 (30) | 35 (20) |
| History of acute myocardial infarction, n (%) | 61 (17) | 37 (21) | 24 (14) |
| Unstable angina, n (%) | 37 (10) | 22 (12) | 15 (9) |
| History of stable angina, n (%) | 75 (21) | 36 (20) | 39 (22) |
| History of primary coronary intervention, n (%) | 127 (36) | 66 (37) | 61 (35) |
| History of coronary artery bypass graft, n (%) | 26 (7) | 14 (8) | 12 (7) |
| History of coronary lesion from previous coronary angiogram, n (%) | 112 (32) | 55 (31) | 57 (32) |
| Coronary stenosis, n (%) | 112 (32) | 55 (31) | 57 (32) |
| Coronary plaque, n (%) | 46 (13) | 25 (14) | 21 (12) |
| History of coronary lesion from previous coronary CT, n (%) | 72 (20) | 37 (21) | 35 (20) |
| Coronary stenosis, n (%) | 55 (16) | 27 (15) | 28 (16) |
| Coronary plaque, n (%) | 37 (10) | 25 (14) | 12 (7) |
| Coronary calcification, n (%) | 59 (17) | 29 (16) | 30 (17) |
| History of peripheral arterial disease, n (%) | 46 (13) | 24 (14) | 22 (13) |
| Aortic dissection, n (%) | 1 (0.3) | 1 (0.6) | 0 (0) |
| Aortic aneurysm, n (%) | 4 (1.1) | 3 (1.7) | 1 (0.6) |
| Arteriosclerosis obliterans, n (%) | 21 (6) | 12 (7) | 9 (5) |
| Carotid artery stenosis, n (%) | 27 (8) | 12 (7) | 15 (9) |
| History of stroke, n (%) | 57 (16) | 29 (16) | 28 (16) |
| Ischemic stroke, n (%) | 52 (15) | 26 (15) | 26 (15) |
| Intracranial hemorrhage, n (%) | 3 (0.9) | 1 (0.6) | 2 (1.1) |
| Hemorrhagic stroke, n (%) | 0 (0) | 0 (0) | 0 (0) |
| Subarachnoid hemorrhage, n (%) | 2 (0.6) | 2 (1.1) | 0 (0) |
| History of transient ischemic attack, n (%) | 7 (1.98) | 4 (2) | 3 (1.7) |
| History of abnormal ankle brachial index, n (%) | 32 (9) | 16 (9) | 16 (9) |
| History of intima media thickness, n (%) | 244 (69) | 117 (66) | 127 (72) |
| History of hypertension, n (%) | 270 (76) | 137 (77) | 133 (76) |
| Family history of coronary artery disease, n (%) | 55 (16) | 21 (12) | 34 (19) |
| Smoker, n (%) | 195 (55) | 92 (52) | 103 (59) |
| Current smoker, n (%) | 54 (15) | 30 (17) | 24 (14) |
| Past smoker, n (%) | 141 (40) | 62 (35) | 79 (45) |
| Drinker, n (%) | 149 (42) | 75 (42) | 74 (42) |
| Current drinker, n (%) | 52 (15) | 27 (15) | 25 (14) |
| Occasional drinker, n (%) | 97 (27) | 48 (27) | 49 (28) |
| History of drug allergy, n (%) | 22 (6) | 10 (6) | 12 (7) |
| Dipeptidyl peptidase-4 inhibitors before enrollment, n (%) | 290 (82) | 145 (82) | 145 (82) |
| Alogliptin, n (%) | 48 (14) | 21 (12) | 27 (15) |
| Anagliptin, n (%) | 7 (2) | 2 (1) | 5 (3) |
| Linagliptin, n (%) | 34 (10) | 19 (11) | 15 (9) |
| Saxagliptin, n (%) | 9 (3) | 6 (3) | 3 (2) |
| Sitagliptin, n (%) | 111 (31) | 52 (29) | 59 (34) |
| Teneligliptin, n (%) | 16 (5) | 8 (5) | 8 (5) |
| Vildagliptin, n (%) | 65 (18) | 37 (21) | 28 (16) |
| Anti-diabetic drugs, n (%) | 243 (69) | 124 (70) | 119 (68) |
| Biguanides, n (%) | 171 (48) | 87 (49) | 84 (48) |
| Thiazolidines, n (%) | 56 (16) | 25 (14) | 31 (18) |
| Sulfonylureas, n (%) | 83 (24) | 46 (26) | 37 (21) |
| Alpha-glucosidase inhibitors, n (%) | 56 (16) | 28 (16) | 28 (16) |
| Glinides, n (%) | 9 (3) | 7 (4) | 2 (1.1) |
| Insulins, n (%) | 28 (8) | 13 (7) | 15 (9) |
| Sodium-dependent glucose transporter 2 inhibitors, n (%) | 45 (13) | 27 (15) | 18 (10) |
| Anti-dyslipidemia drugs, n (%) | 353 (100) | 177 (100) | 176 (100) |
| Statins, n (%) | 353 (100) | 177 (100) | 176 (100) |
| Anion exchangers, n (%) | 0 (0) | 0 (0) | 0 (0) |
| Ezetimibes, n (%) | 30 (9) | 18 (10) | 12 (7) |
| Probucols, n (%) | 2 (0.6) | 2 (1.1) | 0 (0) |
| Fibrates, n (%) | 20 (6) | 11 (6) | 9 (5) |
| Eicosapentaenoic acids, n (%) | 31 (9) | 16 (9) | 15 (9) |
| Nicotinic acids, n (%) | 1 (0.3) | 0 (0) | 1 (0.6) |
| Sterols, n (%) | 0 (0) | 0 (0) | 0 (0) |
| Aspirin, n (%) | 153 (43) | 84 (47) | 69 (39) |
| Ticlopidine, n (%) | 13 (4) | 7 (4) | 6 (3) |
| β-blockers, n (%) | 84 (24) | 44 (25) | 40 (23) |
| Angiotensin-converting enzyme inhibitors, n (%) | 33 (9) | 22 (12) | 11 (6) |
| Angiotensin II receptor blockers, n (%) | 177 (50) | 87 (49) | 90 (51) |
| Calcium channel blockers, n (%) | 164 (46) | 85 (48) | 79 (45) |
| Nitroglycerines, n (%) | 19 (5) | 12 (7) | 7 (4) |
| Diuretics, n (%) | 52 (15) | 30 (17) | 22 (13) |
| Aldosterone antagonists, n (%) | 14 (4) | 8 (5) | 6 (3) |
| White blood cell-mm3, median [IQR] | 6100 [5200–7200] | 6365 [5325–7500] | 5900 [4900–7000] |
| Red blood cell- × 104mm3, median [IQR] | 460 [426–490] | 465 [426–496] | 453 [426–484] |
| Hemoglobin-g/dL, median [IQR] | 13.9 [13.0–15.1] | 14.0 [13.2–15.2] | 13.9 [12.7–14.8] |
| Hematocrit-%, median [IQR] | 41.9 [38.9–44.8] | 42.6 [39.1–45.4] | 41.6 [38.5–44.0] |
| Platelet- × 104mm3, median [IQR] | 20.8 [17.9–24.8] | 21.1 [17.4–24.7] | 20.8 [18.3–24.9] |
| Fasting blood glucose-mg/dL, median [IQR] | 133 [116–158] | 136 [115–161] | 128 [117–153] |
| Aspartate transaminase-IU/L, median [IQR] | 22 [18–28] | 24 [18–30] | 20 [18–26] |
| Alanine aminotransferase-IU/L, median [IQR] | 21 [15–30] | 22 [16–34] | 19 [15–26] |
| γ- glutamyl transpeptidase-IU/L, median [IQR] | 26 [18–41] | 30 [18–46] | 25 [18–36] |
| Creatine kinase-IU/L, median [IQR] | 99 [71–138] | 93 [69–136] | 102 [73–144] |
| Blood urea nitrogen-mg/dL, median [IQR] | 15.9 [12.9–20.0] | 15.3 [12.8–19.7] | 16.1 [13.0–20.0] |
| Creatinine-mg/dL, median [IQR] | 0.80 [0.66–0.97] | 0.78 [0.66–0.97] | 0.81 [0.66–0.98] |
| Estimated glomerular filtration rate-mL/min/1.73 m2, median [IQR] | 67.69 [55.06–80.59] | 68.64 [55.31–83.17] | 66.80 [54.32–78.77] |
| Hemoglobin A1c-%, median [IQR] | 6.9 [6.4–7.4] | 7.0 [6.4–7.6] | 6.8 [6.4–7.3] |
| LDL cholesterol-mg/dL, median [IQR] | 108 [96–122] | 112 [97–123] | 106 [94–121] |
| Total cholesterol-mg/dL, median [IQR] | 185 [169–204] | 188 [171–207] | 183 [167–199] |
| HDL cholesterol-mg/dL, median [IQR] | 52 [45–61] | 52 [45–60] | 53 [45–62] |
| Triglycerides-mg/dL, median [IQR] | 120 [86–167] | 129 [95–186] | 114 [80–159] |